Home / Going-concern warnings / Seres Therapeutics, Inc.
Filed 2026-03-12 路 Form 10-K 路 Accession 0001193125-26-103276 micro
Price before filing: $8.93 (2026-03-11 close, split/dividend-adjusted)
Market cap at flag: $86.7M (2026-03-12) 路 Latest: $23.7M (2026-10-16)
| Window | MCRB | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -3.9% | +1.7% | -5.6% | 2026-04-13 |
| 90 days | -27.3% | +7.6% | -34.9% | 2026-06-10 |
| 180 days | -37.7% | +13.9% | -51.6% | 2026-09-08 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 4 insiders sold $4K (4 sales)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-02-15 | DesRosier Thomas See Remarks | Sale | 78 | $8.47 | $661 | yes | Form 4 |
| 2026-02-15 | Henn Matthew R See Remarks | Sale | 89 | $8.47 | $754 | yes | Form 4 |
| 2026-02-15 | Shaff Eric D. Director | Sale | 259 | $8.47 | $2K | yes | Form 4 |
| 2026-02-15 | Young Teresa L. See Remarks | Sale | 75 | $8.47 | $635 | yes | Form 4 |
| 2026-03-12: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-12-12 to 2026-04-11. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"As discussed in Note 1 to the consolidated financial statements, the Company incurred recurring losses from operations and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Going-concern opinion issued by: PricewaterhouseCoopers LLP
Source: independent auditor report in Form 10-K (period 2025-12-31)
Why this score: in auditor's report
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.